Caplin Point Buys $473 Million Portfolio of US-Approved Injectable and Ophthalmic ANDAs

Caplin Point Laboratories Limited ( (IN:CAPLIPOINT) ) has shared an update.

Caplin Point Laboratories, through its subsidiaries Caplin Steriles and Caplin One Labs, has acquired 10 approved Abbreviated New Drug Applications (ANDAs) for injectable and ophthalmic products from a leading multinational generic manufacturer, covering an addressable market of $473.2 million for the year ended August 2025. The deal strengthens Caplin’s U.S. portfolio—now including select oncology injectables to be commercialized from its new oncology facility in Kakkalur—and supports its strategy to deepen presence in the U.S. while progressively rolling out these products to key non-U.S. markets such as Mexico, Canada, the European Union and Brazil, reinforcing the company’s positioning as a growing global player in sterile and oncology generics.

More about Caplin Point Laboratories Limited

Caplin Point Laboratories Limited is a fast-growing Indian pharmaceutical company focused on emerging markets in Latin America and Africa, offering a complete range of finished dosage forms from state-of-the-art manufacturing facilities. The company, along with its sterile injectables arm Caplin Steriles Limited and oncology-focused subsidiary Caplin One Labs Limited, has built a strong regulatory footprint in the US and multiple non-US markets, and has been repeatedly recognized for its consistent growth, profitability, and business excellence.

Average Trading Volume: 4,143

Technical Sentiment Signal: Hold

Current Market Cap: 143.1B INR

For a thorough assessment of CAPLIPOINT stock, go to TipRanks’ Stock Analysis page.